ArticleCancers2021
A Population-Based Analysis of 30-Year Mortality among Five-Year Survivors of Adolescent and Young Adult Cancer: The Roles of Primary Cancer, Subsequent Malignancy, and Other Health Conditions.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Risk stratification and long-term monitoring in pediatric thyroid cancer: predictive markers for disease persistence.European thyroid journal · 2026Article
- Cancer Screening Uptake and Usual Source of Care Among Hispanic Survivors of Adolescent and Young Adult Cancer.Journal of adolescent and young adult oncology · 2026Article
- Building Pediatric Cancer Cohorts and Accessing Data Using Childhood Cancer Data Initiative Tools.JCO clinical cancer informatics · 2025Article
- Article
- Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Life after cancer matters: supporting 2.1 million survivors of adolescent and young adult cancer.Journal of the National Cancer Institute · 2025Article
- Clinical Implications and Novel Insights into Adolescent Primary Liver Cancer: A Nightmare for Adolescents?Journal of hepatocellular carcinoma · 2025Article
- Excess mortality in young cancer survivors compared with the general population in Italy: a retrospective study from the Italian population-based cohort of adolescents and young adult cancer survivors.Frontiers in oncology · 2025Article
- Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know.PharmacoEconomics · 2024Article
- Survivorship after adolescent and young adult cancer: models of care, disparities, and opportunities.Journal of the National Cancer Institute · 2024Article
- Long-Term Risk of Subsequent Malignant Neoplasms Among Childhood and Adolescent Lymphoma Survivors (1975-2013): A Population-Based Predictive Nomogram.The oncologist · 2023Article
- The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Prevalence and correlates of skin examination among ethnically diverse young adult survivors of childhood cancer.Cancer medicine · 2023Article
- Adolescent and young adult cancers: unmet needs and closing the gaps.Current opinion in pediatrics · 2023Review
- Cause of Death During Renal Cell Carcinoma Survivorship: A Contemporary, Population-Based Analysis.Frontiers in oncology · 2022Article
- Cause of death during upper tract urothelial carcinoma survivorship: A contemporary, population-based analysis.Frontiers in oncology · 2022Article
- Recent Advances in Pediatric Cancer Research.Cancer research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Despite an aggregate 5-year survival of 85%, many adolescents and young adults (AYAs, 15-39 years old) treated for cancer die prematurely decades later. To develop a more complete understanding of this problem, particularly the role of specific subsequent malignant neoplasms (SMNs), we used the SEER-9 registry to analyze causes of death (COD: Primary cancer, SMN, non-malignant conditions) among 162,317 AYAs diagnosed with first cancer between 1975-2012 and surviving 5 or more years. Cumulative mortality, attributable mortality, standardized mortality ratios (SMRs), and adjusted hazard ratios were determined for each cancer site and COD. At 30 years, cumulative mortality due to primary cancer was matched by that due to all other causes (12.8% 95% CI [12.5%, 13.0%] for primary cancer versus 12.8% [12.5%, 13.1%] for all other causes combined) in the combined cohort, and was overtaken by non-malignant conditions in Hodgkin lymphoma, testicular, cervical/uterine, and thyroid cancers. Overall, SMNs accounted for 20% of malignant deaths, the most common being lung/bronchus (25.6%), colorectal/liver/biliary/pancreas (19.1%), and breast (10.2%). For non-malignant conditions, excess risk was noted overall (SMR 1.37, 95% CI [1.34, 1.40]) and for infectious (1.97 [1.85, 2.10]), renal (1.85 [1.60, 2.13]), cardio/cerebrovascular (1.38 [1.33, 1.43]), and suicide (1.15 [1.04, 1.27]). Racial minorities were at significantly higher risk across all COD. Safer therapy, longitudinal monitoring, and primary/secondary preventive strategies are needed to reduce late mortality in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.